TU Delft and Imperial-founded genetic data analytics software provider BlueBee has been picked up after raising at least $13.5m of funding.

Grand Decade and existing investor Boehringer Ingelheim Venture Fund helped supply $38.2m for the mRNA immunotherapy developer and Vrije Universiteit Brussel spinout.

Uniseed has entered a co-investment pact with BioCurate, a drug discovery fund for early-stage University of Melbourne and Monash University research.

Founded by University of Washington faculty, Proprio has raised series A funding to commercialise its multi-camera surgical imaging system.

Backed by Intel and HTC as of its launch early last year, Proprio has now raised a total of $30m to commercialise its multi-camera surgical imaging system.

Grand Decade and existing investor Boehringer Ingelheim Venture Fund helped supply $38.2m for the mRNA immunotherapy developer and Vrije Universiteit Brussel spinout.

Chalmers Ventures portfolio company Biofrigas has set out plans for a $1.7m IPO but has already issued around $1.2m to existing connections.

The demographic phenomenon of ageing populations will present challenges to both developed and developing nations. Along with the challenges come opportunities, however, and corporate venture capitalists may be a particularly well-positioned group to help with them, as it is the connecting tissue between the world of incumbent corporate industry leaders and the space of disruptive innovation.

The protein degradation-focused drug developer, a spinout from Dana-Farber Cancer Institute, received $150m in series B funding and $20m in venture debt.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.